Cyclopharm Says US Footprint Includes 50 Revenue-Generating Installations, Shares Jump 6%
MT Newswires Live
Mar 31
Cyclopharm (ASX:CYC) said that as of Tuesday, its US footprint includes 50 revenue-generating installations, linked to an additional 331 contracted locations, as well as a further 74 primary installations, within the contracting/installation phase, and 48 sites in active contract review, according to a Tuesday Australian bourse filing.
A draft US and international clinical guideline, which recognized its Technegas lung imaging product as a preferred ventilation agent, is expected to be finalized at the upcoming Society of Nuclear Medicine and Molecular Imaging annual meeting in late May.
Its shares jumped 6% in recent trading on Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.